Isabelle Borget

Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer

Martin Schlumberger, Bogdan Catargi, Isabelle Borget et al. · New England Journal of Medicine · 2012 · 681 citations · Full text

Detection of Circulating Tumor Cells Harboring a Unique <i>ALK</i> Rearrangement in <i>ALK</i>-Positive Non–Small-Cell Lung Cancer

Emma Pailler, Julien Adam, Amélie Barthelemy et al. · Journal of Clinical Oncology · 2013 · 279 citations · Full text

Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study

Rossella Libé, Isabelle Borget, Cristina L. Ronchi et al. · Annals of Oncology · 2015 · 247 citations · Full text

Prognostic Factors, Adrenal Gland, Surgical Oncology +11

A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)

Karim Fizazi, Aline Maillard, Nicolas Penel et al. · Annals of Oncology · 2019 · 240 citations · Full text

Malignant Disease, Medicine, Phase Iii Trial +8

Long-Term Follow-Up of Patients with Papillary and Follicular Thyroid Cancer: A Prospective Study on 715 Patients

Maryse Brassard, Isabelle Borget, Agathe Edet‐Sanson et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 231 citations · Full text